Back to discover
Drug

Amphotericin B

In clinical development
Emerging researchLate-stage developmentSteady momentum
Also known as AMPH-b, Abelcet, AmBisome, Amfotericina B+5 more

AMPH-b, Abelcet, AmBisome, Amfotericina B, Amphotericin B Liposomal, Fungizone, Amphotericinum B, Amphotéricine B, amphotericine B.

RxNorm732ChEMBLCHEMBL267345ATCJ02AA01ATCA01AB04ATCA07AA07ATCG01AA03UNII7XU7A7DROE
4
Research papers
2
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Amphotericin B in the Treatment of Breakthrough Invasive Fungal Disease in Hematological Patients Receiving Triazole Prophylaxis

Clinical trial2026-04-30Results expected Q4 2028 · ClinicalTrials.gov

Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis

Clinical trial2026-01-05Primary completion · ClinicalTrials.gov

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Clinical trial2024-10-01Primary completion · ClinicalTrials.gov

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

Clinical trial2024-08-07Results posted · ClinicalTrials.gov

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial

Clinical trial2023-08-30Completed · ClinicalTrials.gov

<i>Candida auris</i> Genetics and Emergence.

Research2023-07-05Annual review of microbiology

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial

Clinical trial2023-02-15Completed · ClinicalTrials.gov

Antifungal Treatment of Cryptococcal Meningitis

Clinical trial2022-03-30Primary completion · ClinicalTrials.gov

A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

Clinical trial2021-11-04Results posted · ClinicalTrials.gov

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.

Research2020-12-14The Lancet. Infectious diseases

Antibiotic-induced microbiome depletion alters metabolic homeostasis by affecting gut signaling and colonic metabolism.

Research2018-07-20Nature communications

Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Research2016-06-29Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Amphotericin B
Aliases & brands
AMPH-bAbelcetAmBisomeAmfotericina BAmphotericin B LiposomalFungizoneAmphotericinum BAmphotéricine Bamphotericine B
RxNorm CUI
732
ChEMBL ID
CHEMBL267345
ATC codes
J02AA01A01AB04A07AA07G01AA03
UNII
7XU7A7DROE

Clinical trials

35 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
35
registered trials across all phases
LATEST COMPLETION 2023
2
Active studies
2
Recruiting
24
Late-stage (III+)
26
Completed
7
Discontinued
PHASE DISTRIBUTIONn = 35
Phase 11Phase 1 / 22Phase 28Phase 2 / 31Phase 310Phase 43Phase N / A10

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial

CompletedPH IVAin Shams Universityn=562023

Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation

Unknown statusPH IVCapital Medical Universityn=4002010

The Strategy Antifungal Empirical Traditional is Again Justified in Prolonged Neutropenias ". Study "PREVERT"

TerminatedPH IVAssistance Publique - Hôpitaux de Parisn=3002006

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3

Unknown statusPH IIIMatinas BioPharma Nanotechnologies, Inc.n=2702025

Antifungal Treatment of Cryptococcal Meningitis

Unknown statusPH IIIShanghai Public Health Clinical Centern=402022

Recent completions

Trials that read out recently, adding to the completed evidence base.

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection In Preterm Neonates: A Randomized Control Trial

CompletedPH IVAin Shams Universityn=562023

Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial

CompletedPH I/IIMatinas BioPharma Nanotechnologies, Inc.n=1782023

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of Encochleated Amphotericin B (CAMB/MAT2203) in Patients With Mucocutaneous Candidiasis Who Are Refractory or Intolerant to Standard Non-Intravenous Therapies

CompletedPH IIMatinas BioPharma Nanotechnologies, Inc.n=42022

A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis

CompletedPH IIOxford University Clinical Research Unit, Vietnamn=502018

A Phase I/II Dose-Finding Study of High-Dose Fluconazole Treatment in AIDS-Associated Cryptococcal Meningitis

CompletedPH I/IINational Institute of Allergy and Infectious Diseases (NIAID)n=1682017

A Phase II Trial to Evaluate the Safety and Tolerability of Nebulised Amphotericin B Lipid Complex (ABELCET®) in the Prophylaxis of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia in Paediatric Patients With Acute Leukaemia

CompletedPH IIFundació Sant Joan de Déun=322013

Research activity

4 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20162023
Major research themes2
Candida1Candida auris1
Journals, researchers & institutions
Top journals
  • Annual review of microbiology1
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
  • Nature communications1
  • The Lancet. Infectious diseases1
Leading researchers
  • Patterson TF2
  • Bassetti M1
  • Bennett JE1
  • Böll B1
  • Brüggemann R1
  • Chaix A1
  • Chakrabarti A1
  • Chang MW1
Leading institutions
free-text, unnormalised
  • Duke University Medical Center2
  • University of California2
  • California Institute for Medical Research1
  • Center for Discovery and Innovation1
  • Center for Microbiome Innovation1
  • Center of Expertise in Mycology Radboudumc/CWZ1

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Insulin

Studied across 4 of the same disease areas as Amphotericin B in the shared literature.

4 shared diseases1 shared paper
Vancomycin

Studied across 4 of the same disease areas as Amphotericin B in the shared literature.

4 shared diseases1 shared paper
Ampicillin

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
Isavuconazole

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
liposomal amphotericin B

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
Metronidazole

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
Neomycin

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
Voriconazole

Studied across 3 of the same disease areas as Amphotericin B in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials